Cargando…
TAZ and YAP are frequently activated oncoproteins in sarcomas
TAZ (WWTR1) and YAP are transcriptional coactivators and oncoproteins inhibited by the Hippo pathway. Herein we evaluate 159 sarcomas representing the most prevalent sarcoma types by immunohistochemistry for expression and activation (nuclear localization) of TAZ and YAP. We show that 50% of sarcoma...
Autores principales: | Fullenkamp, Colleen A., Hall, Sarah L., Jaber, Omar I., Pakalniskis, Brittany L., Savage, Erica C., Savage, Johanna M., Ofori-Amanfo, Georgina K., Lambertz, Allyn M., Ivins, Stephanie D., Stipp, Christopher S., Miller, Benjamin J., Milhem, Mohammed M., Tanas, Munir R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058666/ https://www.ncbi.nlm.nih.gov/pubmed/27129148 http://dx.doi.org/10.18632/oncotarget.8979 |
Ejemplares similares
-
TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex
por: Merritt, Nicole, et al.
Publicado: (2021) -
A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy
por: Pobbati, Ajaybabu V., et al.
Publicado: (2020) -
Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin
por: Brouwer, Niels J., et al.
Publicado: (2021) -
The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment
por: Mokhtari, Reza Bayat, et al.
Publicado: (2023) -
Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma
por: Bouvier, Corinne, et al.
Publicado: (2016)